PRSS3/mesotrypsin in Prostate Cancer Progression: Implications for Translational Medicine

Overview

Journal Asian J Androl

Specialty Urology

Date 2013 Mar 19

PMID 23503422

Citations 8

Authors

Evette S Radisky

Affiliations

Soon will be listed here.

Citing Articles

Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers.

Sananes A, Cohen I, Allon I, Ben-David O, Shareb R, Yegodayev K Mol Oncol. 2023; 17(11):2337-2355.

PMID: 37609678 PMC: 10620120. DOI: 10.1002/1878-0261.13513.

Serine Protease 3 Promotes Progression of Diffuse Large B-Cell Lymphoma and Serves as a Novel Prognostic Predictor.

Zheng L, Wang X, Zheng W, Huang H Dis Markers. 2023; 2022:1254790.

PMID: 36618965 PMC: 9822761. DOI: 10.1155/2022/1254790.

The roles of proteases in prostate cancer.

Koistinen H, Kovanen R, Hollenberg M, Dufour A, Radisky E, Stenman U IUBMB Life. 2023; 75(6):493-513.

PMID: 36598826 PMC: 10159896. DOI: 10.1002/iub.2700.

CpG Site-Specific Methylation-Modulated Divergent Expression of Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L Front Oncol. 2022; 12:831268.

PMID: 35480112 PMC: 9035874. DOI: 10.3389/fonc.2022.831268.

Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Lin B, Zhou X, Lin S, Wang X, Zhang M, Cao B J Mol Med (Berl). 2017; 95(11):1237-1249.

PMID: 28844099 PMC: 8171496. DOI: 10.1007/s00109-017-1578-5.

References

Nakagawa T, Kollmeyer T, Morlan B, Anderson S, Bergstralh E, Davis B . A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008; 3(5):e2318. PMC: 2565588. DOI: 10.1371/journal.pone.0002318. View

Radisky E, Radisky D . Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15(2):201-12. PMC: 2886087. DOI: 10.1007/s10911-010-9177-x. View

Kelloff G, Sigman C . Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012; 11(3):201-14. DOI: 10.1038/nrd3651. View

Hockla A, Miller E, Salameh M, Copland J, Radisky D, Radisky E . PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res. 2012; 10(12):1555-66. PMC: 3531873. DOI: 10.1158/1541-7786.MCR-12-0314. View

Liotta L, Petricoin 3rd E . -Omics and cancer biomarkers: link to the biological truth or bear the consequences. Cancer Epidemiol Biomarkers Prev. 2012; 21(8):1229-35. PMC: 3761362. DOI: 10.1158/1055-9965.EPI-12-0635. View

Lazebnik Y . What are the hallmarks of cancer?. Nat Rev Cancer. 2010; 10(4):232-3. DOI: 10.1038/nrc2827. View

Salameh M, Soares A, Hockla A, Radisky D, Radisky E . The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J. 2011; 440(1):95-105. PMC: 3380622. DOI: 10.1042/BJ20110788. View

Attard G, de Bono J . Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res. 2011; 17(12):3867-75. DOI: 10.1158/1078-0432.CCR-11-0943. View

Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P . Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294(4):433-9. DOI: 10.1001/jama.294.4.433. View

10.

Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y . PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut. 2010; 59(11):1535-44. DOI: 10.1136/gut.2009.200105. View

11.

Ateeq B, Tomlins S, Laxman B, Asangani I, Cao Q, Cao X . Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med. 2011; 3(72):72ra17. PMC: 3211047. DOI: 10.1126/scitranslmed.3001498. View

12.

Tomlins S, Rhodes D, Yu J, Varambally S, Mehra R, Perner S . The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008; 13(6):519-28. PMC: 2732022. DOI: 10.1016/j.ccr.2008.04.016. View

13.

Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

14.

Radisky E, Radisky D . Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007; 8(3):279-87. DOI: 10.1007/s11154-007-9037-1. View